11-Jun-2026
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)
TipRanks (Fri, 12-Jun 6:00 AM ET)
Biomea Fusion Shareholders Reject Director Nominees, Ratify Auditor
TipRanks (Thu, 11-Jun 7:31 AM ET)
Analysts’ Top Healthcare Picks: Incyte (INCY), Zevra Therapeutics (ZVRA)
TipRanks (Tue, 9-Jun 7:10 AM ET)
TipRanks (Mon, 8-Jun 6:35 AM ET)
Globe Newswire (Fri, 5-Jun 7:32 PM ET)
Globe Newswire (Wed, 3-Jun 8:00 AM ET)
Biomea Fusion to Participate at Upcoming Investor Conferences
Globe Newswire (Tue, 12-May 4:05 PM ET)
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
Globe Newswire (Mon, 11-May 4:54 PM ET)
Globe Newswire (Tue, 5-May 5:50 PM ET)
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Biomea Fusion trades on the NASDAQ stock market under the symbol BMEA.
As of June 11, 2026, BMEA stock price climbed to $1.19 with 750,407 million shares trading.
BMEA has a beta of 2.98, meaning it tends to be more sensitive to market movements. BMEA has a correlation of 0.12 to the broad based SPY ETF.
BMEA has a market cap of $86.04 million. This is considered a Micro Cap stock.
In the last 3 years, BMEA traded as high as $41.69 and as low as $.87.
The top ETF exchange traded funds that BMEA belongs to (by Net Assets): VTI, VXF, IWC.
BMEA has underperformed the market in the last year with a price return of -52.4% while the SPY ETF gained +23.9%. BMEA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -20.7% and -13.8%, respectively, while the SPY returned +9.3% and -2.2%, respectively.
BMEA support price is $1.09 and resistance is $1.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMEA shares will trade within this expected range on the day.